Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

2.

Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.

de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson KJ, Stahl N, Lipsich L, Kyratsous CA, Feldmann H.

Antiviral Res. 2018 Aug;156:64-71. doi: 10.1016/j.antiviral.2018.06.006. Epub 2018 Jun 7.

PMID:
29885377
3.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.

4.

Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice.

Wiehe K, Nicely NI, Lockwood B, Kuraoka M, Anasti K, Arora S, Bowman CM, Stolarchuk C, Parks R, Lloyd KE, Xia SM, Duffy R, Shen X, Kyratsous CA, Macdonald LE, Murphy AJ, Scearce RM, Moody MA, Alam SM, Verkoczy L, Tomaras GD, Kelsoe G, Haynes BF.

J Immunol. 2017 Feb 1;198(3):1047-1055. doi: 10.4049/jimmunol.1601640. Epub 2016 Dec 23.

5.

CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.

Coleman CM, Sisk JM, Halasz G, Zhong J, Beck SE, Matthews KL, Venkataraman T, Rajagopalan S, Kyratsous CA, Frieman MB.

J Virol. 2016 Dec 16;91(1). pii: e01825-16. doi: 10.1128/JVI.01825-16. Print 2017 Jan 1.

6.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.

Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous CA.

PLoS One. 2016 Apr 26;11(4):e0154498. doi: 10.1371/journal.pone.0154498. eCollection 2016.

7.

Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.

Kyratsous CA, Olson W, Stahl N.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5116. doi: 10.1073/pnas.1513935112. Epub 2015 Aug 28. No abstract available.

8.

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.

Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB, Kyratsous CA.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. Epub 2015 Jun 29.

9.

Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice.

Billiard F, Lobry C, Darrasse-Jèze G, Waite J, Liu X, Mouquet H, DaNave A, Tait M, Idoyaga J, Leboeuf M, Kyratsous CA, Burton J, Kalter J, Klinakis A, Zhang W, Thurston G, Merad M, Steinman RM, Murphy AJ, Yancopoulos GD, Aifantis I, Skokos D.

J Exp Med. 2012 May 7;209(5):1011-28. doi: 10.1084/jem.20111615. Epub 2012 Apr 30.

10.

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma.

Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O, Hoffmann A, Elenitoba-Johnson KS, Pagano M.

Nat Cell Biol. 2012 Mar 4;14(4):375-85. doi: 10.1038/ncb2463.

11.

Heat-shock protein fusion vectors for improved expression of soluble recombinant proteins in Escherichia coli.

Kyratsous CA, Panagiotidis CA.

Methods Mol Biol. 2012;824:109-29. doi: 10.1007/978-1-61779-433-9_5.

PMID:
22160895
12.
13.

Complementation of a herpes simplex virus ICP0 null mutant by varicella-zoster virus ORF61p.

Kyratsous CA, Walters MS, Panagiotidis CA, Silverstein SJ.

J Virol. 2009 Oct;83(20):10637-43. doi: 10.1128/JVI.01144-09. Epub 2009 Aug 5.

14.

Chaperone-fusion expression plasmid vectors for improved solubility of recombinant proteins in Escherichia coli.

Kyratsous CA, Silverstein SJ, DeLong CR, Panagiotidis CA.

Gene. 2009 Jul 1;440(1-2):9-15. doi: 10.1016/j.gene.2009.03.011. Epub 2009 Mar 26.

15.

Components of nuclear domain 10 bodies regulate varicella-zoster virus replication.

Kyratsous CA, Silverstein SJ.

J Virol. 2009 May;83(9):4262-74. doi: 10.1128/JVI.00021-09. Epub 2009 Feb 11.

16.

The co-chaperone BAG3 regulates Herpes Simplex Virus replication.

Kyratsous CA, Silverstein SJ.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20912-7. doi: 10.1073/pnas.0810656105. Epub 2008 Dec 16.

17.
18.

BAG3, a host cochaperone, facilitates varicella-zoster virus replication.

Kyratsous CA, Silverstein SJ.

J Virol. 2007 Jul;81(14):7491-503. Epub 2007 May 2.

Supplemental Content

Loading ...
Support Center